Komitet Biotechnologii PAN ; Instytut Chemii Bioorganicznej PAN
Catalytic nucleic acids, ribozymes and deoxyribozymes can act as efficientribonucleases and degrade target RNA molecules by complementary Watson-Crick base pairing and catalytic cleavage of their phosphodiesterinternucleotide bonds. This ability makes ribozymes and deoxyribozymes potent molecular tools for therapeutic applications. Recent achievements inribozymes design and technology enable the preparation of ribozymes whichcan be efficiently expressed in cellular systems, co-localize with the targetmRNA and exhibit high intracellular activity. Several examples of preclinical andclinical trials of ribozymes directed toward viral genes (HBV, HCV, HIV-1) andoncogenes are discussed in this review.
Biotechnologia, vol.61, 2 (2003)-.
0860-7796 ; oai:rcin.org.pl:135641 ; IChB B-57
Biblioteka Instytutu Chemii Bioorganicznej PAN
Licencja Creative Commons Uznanie autorstwa-Na tych samych warunkach 4.0
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Oct 2, 2020
Aug 19, 2020
1307
https://rcin.org.pl/ichb/publication/170581
Edition name | Date |
---|---|
Rybozymy w medycynie | Oct 2, 2020 |
Borkowska, Bożenna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Nowak, Jacek K.
Sierant, Małgorzata Nawrot, Barbara